Grifols, S.A. (GRF.MC)
| Chiusura precedente | 12,52 |
| Aperto | 12,49 |
| Denaro | 12,51 x 0 |
| Lettera | 12,52 x 0 |
| Min-Max giorno | 12,39 - 12,56 |
| Intervallo di 52 settimane | 7,82 - 14,99 |
| Volume | |
| Media Volume | 1.027.847 |
| Capitalizzazione | 7,511B |
| Beta (5 anni mensile) | 0,46 |
| Rapporto PE (ttm) | 73,50 |
| EPS (ttm) | 0,17 |
| Prossima data utili | 02 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 03 giu 2021 |
| Stima target 1A | 18,71 |
GlobeNewswireGrifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and
- GlobeNewswire
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st
- GlobeNewswire
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard medical treatment to increase survival time in patients with decompensated cirrhosis awaiting transplantAlbumin’s antioxidant and anti-inflammatory properties have the potential to mitigate the complications associated with decompensated cirrhosisGrifols continues innovating across its plasma-protein franchise and is committed to applying its ever-growing expertise in a range of therapeutic are
